Nuvectis Pharma, Inc. carries no debt; cash flow comfortably covers obligations.

Nuvectis Pharma, Inc.'s free cash flow has decreased 30.72% from $-12.25M last year to $-16.01M, signaling decreasing performance

Nuvectis Pharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Nuvectis Pharma, Inc. has insufficient data to evaluate this check.

Nuvectis Pharma, Inc. has a net cash position, so leverage is healthy.

Nuvectis Pharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Nuvectis Pharma, Inc. has insufficient data to evaluate this check.

Nuvectis Pharma, Inc.'s short-term assets of $31.71M exceed its short-term liabilities of $13.30M

Nuvectis Pharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Nuvectis Pharma, Inc.'s return on equity of -169.47%, is lower than 15.00%, indicating bad performance

Nuvectis Pharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Nuvectis Pharma, Inc. has insufficient public price history to evaluate earnings stability.

Nuvectis Pharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Nuvectis Pharma, Inc. has negative free cash flow, indicating cash burn

Nuvectis Pharma, Inc.'s yearly earnings has decreased 39.17% since last year from $-19.00M to $-26.44M, signaling decreasing performance

Nuvectis Pharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -317.86% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Nuvectis Pharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Nuvectis Pharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Nuvectis Pharma, Inc. has insufficient public price history to evaluate ROE consistency.

Nuvectis Pharma, Inc. has insufficient data to evaluate this check.

Nuvectis Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nuvectis Pharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Nuvectis Pharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Nuvectis Pharma, Inc. has insufficient data to evaluate this check.

Nuvectis Pharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Nuvectis Pharma, Inc. has a price-to-book ratio of 48.80x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Nuvectis Pharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue